Bigfoot and Abbott Join Forces to Develop and Commercialize Diabetes Management Systems
Bigfoot Biomedical Inc. and Abbott Laboratories Inc. today signed a partnership agreement that calls for the integration of Abbott's FreeStyle Libre CGM into the artificial pancreas system Bigfoot is developing. The move is an endorsement for Abbott's no-calibration, easy-to-use CGM system over other major players in the CGM field, including Dexcom.
You may also be interested in...
Market Intel: Bigfoot Biomedical, Beta Bionics Getting Pumped To Introduce Next-Gen Artificial Pancreas
The insulin pump market, which is dominated by four major players, is facing rising competition from smaller, innovative companies. This second part of a two-part series focuses on five emerging companies: Beta Bionics, Bigfoot Biomedical, Diabeloop, EOFlow and Ypsomed.
Device Debuts: Medtronic MiniMed 670G HCL Insulin Pump; OrbusNeich Sapphire Coronary Balloons; Shockwave Lithoplasty; DePuy Synthes' Fenestrated Spine Screws; Philips Monitoring And Imaging Systems
This edition of Medtech Insight's Device Debuts covers the innovative devices introduced into commercial markets since mid-May, including Medtronic's long-awaited launch of the MiniMed 670G Hybrid Closed Loop insulin pump system, OrbusNeich's entry into the US coronary dilation catheter market, and Shockwave's Lithoplasty system for treating calcified peripheral arteries.
The global diabetes management devices market is expected to exceed $11.2bn by 2020, driven largely by the rising diabetes epidemic. This, in turn, is fueling significant innovation such as next-generation, automated artificial pancreas systems and miniaturized, less-invasive wireless technologies that can continuously track and analyze glucose levels in real-time. This feature looks more closely at these and other potentially groundbreaking new technologies, as well as the competitive landscape of the two major product segments – insulin pumps and blood glucose monitors.